Tobramycin

Manufacturer
REMEDYREPACK INC.
Effective date
2026-01-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
13
Source
full-release
Hydrated at
2026-05-31 21:56:47

Label at a glance#

ProductTobramycin
Active ingredientTOBRAMYCIN
Label structure10 sections

Indications and uses

Tobramycin ophthalmic solution 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

Dosage and administration

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Tobramycin ophthalmic solution 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

Each mL of Tobramycin ophthalmic solution USP, 0.3% contains: Active:tobramycin 0.3% (3 mg). Preservative:benzalkonium chloride 0.01% (0.1 mg). Inactives:boric acid, sodium sulfate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and water for injection. Tobramycin ophthalmic solution 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg.

Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram- negative and gram-positive ophthalmic pathogens.

The chemical structure of tobramycin is:

Molecular Weight = 467.52 Molecular Formula:

C 18H 37N 5O 9

DESCRIPTION
DESCRIPTION

Chemical Name:

0-{3-amino-3-deoxy-α-D-gluco-pyranosyl  (1→4) }-0-{2,6-diamino-2,3,6-trideoxy 

α-D-ribohexo-pyranosyl-(1→6) }-2  deoxystreptamine.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In Vitro Data: In vitrostudies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureusand S. epidermidis(coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgarisstrains, Haemophilus influenzaeand H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticusand some Neisseriaspecies.

Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Tobramycin ophthalmic solution 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Tobramycin ophthalmic solution 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution 0.3% occurs, discontinue use.

PRECAUTIONS

PRECAUTIONS SECTION

General:As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.

Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial ocular infection.

Information for Patients:Do not touch dropper tip to any surface, as this may contaminate the solution.

Pregnancy:Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers:Because of the potential for adverse reactions in nursing infants from tobramycin ophthalmic solution 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use:Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

Geriatric Use:No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions to tobramycin ophthalmic solution 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution 0.3%.

Postmarketing Experience:Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

The following additional adverse reactions have been reported with systemic aminoglycosides:

Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson's disease, because of their potential effect on neuromuscular function.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

HOW SUPPLIED

HOW SUPPLIED SECTION

Tobramycin ophthalmic solution USP, 0.3% is supplied as a 5 mL sterile solution, packaged in a 10 mL white LDPE bottle and natural LDPE nozzle and White HDPE cap as follows:

5 mL containing tobramycin 0.3% (3 mg/mL)

NDC: 70518-1370-00

PACKAGING: 1 in 1 CARTON, 5 mL in 1 BOTTLE, TYPE 0

Storage: Store at 2° to 25°C (36° to 77°F).

After opening, tobramycin ophthalmic solution 0.3% can be used until the expiration date on the bottle.

Repackaged and Distributed By:

Remedy Repack, Inc.

625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

DRUG: Tobramycin

GENERIC: Tobramycin

DOSAGE: SOLUTION/ DROPS

ADMINSTRATION: OPHTHALMIC

NDC: 70518-1370-0

COLOR: white

PACKAGING: 5 mL in 1 BOTTLE

OUTER PACKAGING: 1 in 1 CARTON

ACTIVE INGREDIENT(S):

  • TOBRAMYCIN 3mg in 1mL

INACTIVE INGREDIENT(S):

  • BENZALKONIUM CHLORIDE
  • BORIC ACID
  • SODIUM SULFATE ANHYDROUS
  • TYLOXAPOL
  • SODIUM CHLORIDE
  • SODIUM HYDROXIDE
  • SULFURIC ACID
  • WATER

MM1MM1

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
313415tobramycin 0.3 % Ophthalmic SolutionPSN13
313415tobramycin 3 MG/ML Ophthalmic SolutionSCD13
313415tobramycin 0.3 % Ophthalmic SolutionSY13

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TOBRAMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
95250459-30e4-45c1-b08a-993044f49109Product name220250805
f297c7c1-845a-4369-8c02-c51b92d6ae8eProduct name320240725
551d952d-4ce2-24f0-9ab0-630ad9aae596Product name220231211
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
941f67d9-7f03-56d2-750c-36de24f654dbProduct name320221117
9cfa145f-dbe9-bc02-83c2-692786ef6676Product name920210928
2f9713b8-5e7e-bbcc-b364-1b2c27a63796Product name420210903
32a533bc-01c7-2b9f-bbf7-ecfb0d964277Product name420210625
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
9f5124fb-08b0-4c3e-8e12-a1a6ff310cbaProduct name120150309
745a62af-e1c0-4ca3-6d6e-2b6455b903beProduct name120140508
9ea85abb-fa68-5da6-ab60-2c7eef579000Product name120140508
aa1cd319-ece7-51f7-3a9d-52a64f5f4e81Product name120140508
d029211e-5e6b-725f-3696-ac6ff77da222Product name120140508
ef5b7aed-2b01-3ba8-5a1c-3bc9c9f03bb1Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70518-1370-0Tobramycin1 in 1 CARTONSOLUTION/ DROPS113
70518-1370-0Tobramycin5 mL in 1 BOTTLESOLUTION/ DROPS513

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70069-131-01ML - Milliliter70069-131f390149a-e072-4bec-bacb-7c770ce4c85d12017-08-11

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70518-137070518-1370-0
70069-131

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A207444-001TOBRAMYCINTOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-28

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A207444-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-2884e616aacf4f…
2026-08-18 06:07:402026-07A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-28caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-28011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-2831067a03dcf5…
2025-08-23 18:47 UTC2025-08A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-286a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-28fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-28b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-2803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-282680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-285bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-28d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-28d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-2879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-28301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-281e350fbaab3a…
2024-05-31 18:47 UTC2024-05A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICATRS2017-06-288072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-285c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-285d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-284b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-2874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-2887673890dc5c…
2021-03-12 10:30 UTC2021-03A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-285aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-288869cabd3fbd…
2020-11-12 02:37 UTC2020-11A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28c0c555d07b60…
2019-12-14 00:12 UTC2019-12A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-283f01610625f2…
2019-09-15 20:21 UTC2019-09A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28b00525d2431f…
2019-07-19 19:46 UTC2019-07A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-286a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-281c564ffb4f44…
2023-12-20 04:57 UTC2023-12A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-289b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-283f0d92c62455…
2023-05-13 08:27 UTC2023-05A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28053a50430f4f…
2023-01-26 05:58 UTC2023-01A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-283bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-283a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A207444-001TOBRAMYCIN0.3%SOLUTION/DROPS / OPHTHALMICAT2017-06-28f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A207444-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A207444-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A207444-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A207444-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A207444-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A207444-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A207444-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A207444-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A207444-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A207444-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A207444-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A207444-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A207444-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A207444-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A207444-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A207444-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A207444-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A207444-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A207444-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A207444-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A207444-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A207444-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A207444-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A207444-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A207444-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A207444-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A207444-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A207444-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A207444-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A207444-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A207444-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A207444-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A207444-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A207444-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A207444-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A207444-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A207444-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A207444-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A207444-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A207444-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TobramycinTOBRAMYCINREMEDYREPACK INC.3596dacc-6abc-45eb-8085-fa7aaa580a1c2026-01-21Warnings, Adverse reactionsExact identifier
ndc (package): 70518-1370-0
ndc (product): 70518-1370
ndc11 (package): 70518137000
spl id: 48eba7d7-d524-0680-e063-6394a90af4c1
spl set id: 3596dacc-6abc-45eb-8085-fa7aaa580a1c
TobramycinTOBRAMYCINSomerset Therapeutics, LLC7333280d-5d2a-4609-ab93-3ab7031b65db2025-07-10Warnings, Adverse reactionsExact identifier
ndc (product): 70069-131

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.